Mercedes Salgado Fernández

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

Bruno Bockorny, Teresa Macarulla, Valerya Semenisty et al. · Clinical Cancer Research · 2021 · 78 citations · Full text

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial

Enrique Aranda, José María Viéitez, Auxiliadora Gómez‐España et al. · ESMO Open · 2020 · 59 citations · Full text

SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)

Andrés J. Muñoz Martín, Enrique Gallardo, Ignacio Escobar et al. · Clinical & Translational Oncology · 2020 · 53 citations · Full text

Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers

Ana Fernández Montés, Nieves Martínez Lago, Marta Covela Rúa et al. · Cancer Medicine · 2019 · 37 citations · Full text

Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs).

Javier Sastre, José María Viéitez, Maria Auxilidora Gomez-España et al. · Journal of Clinical Oncology · 2019 · 26 citations

Prognosis, Pathology, Arm B +17